RND-001

RND-001 is an investigational drug candidate being co-developed by AMO Pharma and Ranedis Pharmaceuticals for the treatment of rare genetic diseases, particularly certain lysosomal storage disorders and other conditions affecting the central nervous system. Public information describes it as a targeted therapy aimed at disease mechanisms underlying these inherited metabolic disorders, but specific molecular modality, target, and route of administration have not been disclosed. The program is in early-stage development, and detailed pharmacology, mechanism of action, and clinical data have not yet been made publicly available.